在人类心力衰竭中诱导性氧化合成酶的表达
G A Haywood1, P S Tsao, H E von der Leyen
1Department of Cardiological Sciences, St. George's Hospital, London, UK.
Circulation
|March 15, 1996
概括
诱导性氧化合成酶 (iNOS) 在心力衰竭患者的心脏细胞中表达,这表明它在扩张性心肌病和缺血性心脏病等疾病中的作用.
科学领域:
- 心血管科学 心血管科学
- 分子生物学分子生物学
- 病理生理学 病理生理学
背景情况:
- 氧化 (NO) 合成变化与心力衰竭有关.
- 虽然内皮NOS (eNOS) 被研究,可诱导NOS (iNOS) 的作用仍然不清楚.
研究的目的:
- 研究诱导性氧化合成酶 (iNOS) 在人类心力衰竭中的表达和重要性.
主要方法:
- 分析了心力衰竭患者,供体心脏和对照组的腹腔心肌中的iNOS mRNA和蛋白质表达.
- 使用逆转录-聚合酶链反应 (RT-PCR) 和免疫组织化学.
- 西方斑点分析证实了iNOS蛋白质水平.
主要成果:
- 在71%的心力衰竭患者中表达iNOS,但在对照组中表达不到iNOS (P<.0001).
- iNOS mRNA和蛋白质被检测到心脏肌细胞在失败的心脏的所有四个室.
- 表达与心房 natriuretic (ANP) 相关联,这是心室衰竭的标志物.
结论:
- 诱导性NOS (iNOS) 表现为失败的人类心脏肌细胞.
- iNOS可能在扩张性心肌病变 (DCM),缺血性心脏病 (IHD) 和膜性心脏病 (VHD) 的病理生理学中发挥作用.
相关概念视频
Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...


